Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (68 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > reading material
View:
Post by DJDawg on Mar 26, 2021 12:33pm

reading material

Hello from TLT newbie to long haulers!

Reading up on TLD-1433 and saw the references to it having the potential for xray activation. Are there journal articles about this that I can read? I looked around the Theralase website and didn't find any specifics on what the studies showed. Obviously that is a huge thing as would impact deeper tissue activation. Any link or reference would be appreciated.
Comment by Jaro1977 on Mar 26, 2021 12:45pm
In preclinical trials, TLD-1433, when activated by radiation therapy has been demonstrated to be effective in the destruction of human GBM cancer cells. In a 2017, Company news release, Dr. Pavel Kaspler, PhD, Theralase Research Scientist stated that, “Radiation therapy followed by NIR laser light activation of TLD-1433 is a new and unexpected discovery by the members of our research team under ...more  
Comment by DJDawg on Mar 26, 2021 1:17pm
Great info. Thanks. So they need to activate by xray followed by NIR laser. Doesn't that mean that it wouldn't be as good as hoped for deep tissue or intracranial malignancy?
Comment by fredgoodwinson on Mar 26, 2021 2:09pm
This discovery has far reaching implications, including: targeting cancers that are difficult, if not impossible to reach with conventional laser light sources, such as GBM brain tumours or deep tissue related cancers.”  
Comment by enriquesuave on Mar 26, 2021 2:24pm
The combination of both X-rays and NIR has an even greater anti Tumor effect, but they can opt to only use X-rays and treat multiple times  IMO   
Comment by DJDawg on Mar 26, 2021 2:25pm
Ok. That makes sense. Good to know!
Comment by enriquesuave on Mar 26, 2021 2:28pm
https://stockhouse.com/news/press-releases/2017/09/25/theralase-lead-anti-cancer-drug-effective-in-the-destruction-of-brain-cancer  
Comment by menoalittle on Mar 26, 2021 12:46pm
>> Are there journal articles about this that I can read?  Nah.  Probably more like science fiction stuff at this point.  There's a scene from the movie "Elysium" that sorta depicts it... (I posted a link to it here some time back...)
Comment by enriquesuave on Mar 26, 2021 1:03pm
Normally company was supposed to complete 2nd animal model of X-ray activation of Rutherin for GBM and NSCLC by Q1.  I hope we see something soon on that.Quarterly report due in April, maybe something on that?    
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 68 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250